Simon Llewellyn


Simon is a partner in the Dispute Resolution team whose practice focuses on multi-jurisdictional patent litigation across all industry sectors, but particularly on the various aspects of the healthcare sector.

Simon has litigated high-profile cases before the Supreme Court, Court of Appeal and High Court concerning both patents and SPCs. His experience includes cases involving blockbuster small molecule, antibody, and non-biological complex drugs, and medical devices. Simon’s expertise also encompasses the chemical sector, and he has assisted in cases involving polymers and industrial chemical processes.

Much of Simon’s work involves cross-border litigation and he has extensive experience assisting as co-counsel in litigation taking place across Europe and elsewhere, including the US and Asia. Simon’s strong scientific background, which includes a doctorate in chemistry from the University of Oxford and post-doctoral research experience, gives him a deep understanding of the technical side of the healthcare and chemical sectors. Coupled with his cross-border patent litigation experience, this means Simon is very well-placed to assist his clients to develop successful patent enforcement and defence strategies.

Simon joined the firm in 2018, having started his career at another London-based patent firm.

Simon is also a regular volunteer with the Holborn Community Association After School STEM Club, which helps children in Holborn to develop their scientific understanding practically through STEM activities.

“Manages pan-European pharma disputes on a Champions League level"
Juve Patent (2021)


  • MSci Chemistry (Imperial College London)
  • DPhil Organometallic Chemistry (University of Oxford)
  • LLB (Legal Practice)
  • Diploma in IP Law & Practice (University of Oxford)
  • Higher Rights of Audience (Civil)
  • Solicitor
  • UPC Representative

Key Cases

  • Accord Healthcare Limited v Celgene Corporation ((REVLIMID®) – patent validity – High Court)
  • Generics v Yeda (validity/infringement of dosage regimen patent – High Court)
  • Actavis v Icos (validity of formulation patent – High Court)
  • Synthon v Teva (validity of process patent – Court of Appeal)
  • Servier v Apotex (damages – Supreme Court)
  • KCI v Smith & Nephew (preliminary injunction, medical devices patent – High Court)